Business Insider

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
Nasdaq

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
Benzinga.com

Armed With Donation From Trial Participant's Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug

Cognition Therapeutics Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including Dementia with Lewy Bodies (DLB), just received assistance in those ...
Seeking Alpha

Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX),, a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has ...